Skip to main content
. 2023 Jan 16;12(1):127–140. doi: 10.21037/tlcr-22-852

Figure 3.

Figure 3

Subgroup analysis of ORR in NSCLC patients treated with camrelizumab. ORR, objective response rate; CI, confidence interval; NSCLC, non-small cell lung cancer; HBV, hepatitis B virus.